Eli Lilly's GLP-1 Drug Market Outlook Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LLY?
Source: Fool
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound drugs saw sales increase by 99% and 175% respectively in 2025, establishing the company as a leader in the GLP-1 drug market; however, investors may be overly optimistic about its future prospects.
- Valuation Risks: With a price-to-earnings ratio of 44, significantly higher than the S&P 500's 28 and the pharmaceutical sector's 23, Eli Lilly's stock reflects high market expectations for its GLP-1 success, warranting caution from investors.
- Increased Competitive Pressure: While Eli Lilly leads the GLP-1 space, competitors like Novo Nordisk continue to innovate, and others such as Pfizer are also exploring this market, posing potential threats to Eli Lilly's market position in the future.
- Patent Protection Challenges: Eli Lilly's drugs are subject to limited patent protection, which could lead to generic competition in the next decade, significantly impacting revenue; investors need to consider this potential risk when evaluating the company's future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 983.260
Low
950.00
Averages
1192
High
1500
Current: 983.260
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's GLP-1 Drugs Spark Investment Frenzy
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound drugs saw sales increase by 99% and 175% respectively in 2025, positioning the company as a leader in the GLP-1 drug market, despite ongoing fierce competition.
- High Valuation Risk: With a price-to-earnings ratio of 44, significantly above the S&P 500's 28 and the pharmaceutical sector's 23, it suggests that investors may be overly optimistic about future growth, increasing risk.
- High Revenue Dependency: Currently, Mounjaro and Zepbound account for 56% of Eli Lilly's revenue, indicating a heavy reliance on these two products, and any loss of market dominance could severely impact overall performance.
- Patent Expiration Threat: Given the limited duration of drug patent protections, Eli Lilly may face generic competition in the next decade, which could pressure revenues, prompting investors to carefully assess the long-term investment value.
See More
Eli Lilly's GLP-1 Drug Market Outlook Analysis
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound drugs saw sales increase by 99% and 175% respectively in 2025, establishing the company as a leader in the GLP-1 drug market; however, investors may be overly optimistic about its future prospects.
- Valuation Risks: With a price-to-earnings ratio of 44, significantly higher than the S&P 500's 28 and the pharmaceutical sector's 23, Eli Lilly's stock reflects high market expectations for its GLP-1 success, warranting caution from investors.
- Increased Competitive Pressure: While Eli Lilly leads the GLP-1 space, competitors like Novo Nordisk continue to innovate, and others such as Pfizer are also exploring this market, posing potential threats to Eli Lilly's market position in the future.
- Patent Protection Challenges: Eli Lilly's drugs are subject to limited patent protection, which could lead to generic competition in the next decade, significantly impacting revenue; investors need to consider this potential risk when evaluating the company's future.
See More
Novo Nordisk Faces Intensifying Competition in Obesity Drug Market
- Disappointing Trial Results: Novo Nordisk's obesity drug CagriSema underperformed against Eli Lilly's Zepbound in a comparative trial, with Zepbound achieving an average weight loss of 25.5% compared to CagriSema's 23%, intensifying pressure on Novo Nordisk in this rapidly growing market.
- Potential of UBT251: Research in China indicates that UBT251 led to a mean weight loss of up to 19.7% over 24 weeks, and although still in mid-stage trials, its mechanism targeting three different gut hormones may enhance efficacy, potentially allowing it to carve out a niche in the market.
- Intensifying Market Competition: Eli Lilly's new drug retatrutide achieved a best-in-class weight loss of 28.7% in a recent phase 3 study, presenting significant competitive pressure for Novo Nordisk, as even if UBT251 performs well in future trials, reclaiming market leadership may remain elusive.
- Future Outlook: Despite challenges, Novo Nordisk has the opportunity to maintain its position as the second-leading player in the fast-growing weight loss drug market through UBT251 and other candidates, with the market projected to exceed $100 billion in sales over the next decade, suggesting potential for recovery if new drugs succeed.
See More
Novo Nordisk Struggles in Weight Loss Market Against Eli Lilly
- Intensifying Market Competition: Novo Nordisk's weight loss drug Wegovy has been surpassed by Eli Lilly's Zepbound in the rapidly growing market, indicating a weakening competitive position that could impact future market share.
- Disappointing Clinical Trial Results: Recent clinical trials showed that Novo Nordisk's new drug CagriSema lagged behind Zepbound, which achieved an average weight loss of 25.5%, suggesting that even new launches may not allow Novo Nordisk to catch up with its rival.
- Potential of New Drug: Novo Nordisk's acquisition of UBT251 demonstrated a 19.7% weight loss in a study conducted in China, and while this result requires further validation, its multi-agonist mechanism could yield better outcomes in future trials, enhancing the company's market position.
- Market Outlook Analysis: Despite current challenges, Novo Nordisk's stock is near multi-year lows, and with the weight loss market projected to exceed $100 billion in the next decade, the company could rebound if UBT251 and other candidates perform well.
See More
Novo Nordisk's New Drug Faces Competitive Pressure
- Clinical Trial Setbacks: Novo Nordisk's obesity drug CagriSema underperformed against Eli Lilly's Zepbound, achieving only a 23% average weight loss over 84 weeks compared to Zepbound's 25.5%, indicating challenges in maintaining competitiveness in the fast-growing weight loss market.
- Potential of UBT251: In a study conducted in China, UBT251 demonstrated a mean weight loss of up to 19.7% in just 24 weeks, leveraging a mechanism that mimics three gut hormones to enhance weight loss efficacy, suggesting it could outperform existing competitors if late-stage trials are favorable.
- Market Outlook Analysis: Despite promising initial results for UBT251, uncertainties remain regarding its approval in the U.S., and Eli Lilly's retatrutide has set a high bar with a 28.7% weight loss in 68 weeks, intensifying competitive pressures on Novo Nordisk.
- Industry Competitive Landscape: With the weight loss market projected to exceed $100 billion in sales over the next decade, Novo Nordisk must accelerate its drug development efforts to maintain its position as the second-leading player, even as its stock hovers near multi-year lows, indicating potential for recovery.
See More
Novo Nordisk and Hims End Feud, Announce Partnership
- Partnership Restoration: Novo Nordisk has decided to sell its weight-loss drug on Hims' telehealth platform, ending their public feud, with an official announcement expected on Monday, indicating a strategic shift in both companies' market approaches.
- Legal Dispute Context: Last month, Novo Nordisk sued Hims for marketing a compounded version of its new weight-loss pill, alleging patent violations related to the ingredient in Wegovy, highlighting the pharmaceutical industry's strong emphasis on intellectual property rights.
- Intensifying Market Competition: The weight-loss drug market is facing increased competition due to recent supply shortages, with the FDA planning to enhance scrutiny of copycat weight-loss drugs, potentially reshaping market dynamics and prompting companies to reassess their product strategies.
- Significant Stock Price Fluctuations: Hims' stock surged 39.77% to $22 in after-hours trading, while Novo Nordisk's stock rose 2.12% to $39.40, reflecting the market's positive response to the new partnership and investor interest in the weight-loss drug market outlook.
See More
Eli Lilly's GLP-1 Drugs Spark Investment Frenzy
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound drugs saw sales increase by 99% and 175% respectively in 2025, positioning the company as a leader in the GLP-1 drug market, despite ongoing fierce competition.
- High Valuation Risk: With a price-to-earnings ratio of 44, significantly above the S&P 500's 28 and the pharmaceutical sector's 23, it suggests that investors may be overly optimistic about future growth, increasing risk.
- High Revenue Dependency: Currently, Mounjaro and Zepbound account for 56% of Eli Lilly's revenue, indicating a heavy reliance on these two products, and any loss of market dominance could severely impact overall performance.
- Patent Expiration Threat: Given the limited duration of drug patent protections, Eli Lilly may face generic competition in the next decade, which could pressure revenues, prompting investors to carefully assess the long-term investment value.
See More
Eli Lilly's GLP-1 Drug Market Outlook Analysis
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound drugs saw sales increase by 99% and 175% respectively in 2025, establishing the company as a leader in the GLP-1 drug market; however, investors may be overly optimistic about its future prospects.
- Valuation Risks: With a price-to-earnings ratio of 44, significantly higher than the S&P 500's 28 and the pharmaceutical sector's 23, Eli Lilly's stock reflects high market expectations for its GLP-1 success, warranting caution from investors.
- Increased Competitive Pressure: While Eli Lilly leads the GLP-1 space, competitors like Novo Nordisk continue to innovate, and others such as Pfizer are also exploring this market, posing potential threats to Eli Lilly's market position in the future.
- Patent Protection Challenges: Eli Lilly's drugs are subject to limited patent protection, which could lead to generic competition in the next decade, significantly impacting revenue; investors need to consider this potential risk when evaluating the company's future.
See More
Novo Nordisk Faces Intensifying Competition in Obesity Drug Market
- Disappointing Trial Results: Novo Nordisk's obesity drug CagriSema underperformed against Eli Lilly's Zepbound in a comparative trial, with Zepbound achieving an average weight loss of 25.5% compared to CagriSema's 23%, intensifying pressure on Novo Nordisk in this rapidly growing market.
- Potential of UBT251: Research in China indicates that UBT251 led to a mean weight loss of up to 19.7% over 24 weeks, and although still in mid-stage trials, its mechanism targeting three different gut hormones may enhance efficacy, potentially allowing it to carve out a niche in the market.
- Intensifying Market Competition: Eli Lilly's new drug retatrutide achieved a best-in-class weight loss of 28.7% in a recent phase 3 study, presenting significant competitive pressure for Novo Nordisk, as even if UBT251 performs well in future trials, reclaiming market leadership may remain elusive.
- Future Outlook: Despite challenges, Novo Nordisk has the opportunity to maintain its position as the second-leading player in the fast-growing weight loss drug market through UBT251 and other candidates, with the market projected to exceed $100 billion in sales over the next decade, suggesting potential for recovery if new drugs succeed.
See More
Novo Nordisk Struggles in Weight Loss Market Against Eli Lilly
- Intensifying Market Competition: Novo Nordisk's weight loss drug Wegovy has been surpassed by Eli Lilly's Zepbound in the rapidly growing market, indicating a weakening competitive position that could impact future market share.
- Disappointing Clinical Trial Results: Recent clinical trials showed that Novo Nordisk's new drug CagriSema lagged behind Zepbound, which achieved an average weight loss of 25.5%, suggesting that even new launches may not allow Novo Nordisk to catch up with its rival.
- Potential of New Drug: Novo Nordisk's acquisition of UBT251 demonstrated a 19.7% weight loss in a study conducted in China, and while this result requires further validation, its multi-agonist mechanism could yield better outcomes in future trials, enhancing the company's market position.
- Market Outlook Analysis: Despite current challenges, Novo Nordisk's stock is near multi-year lows, and with the weight loss market projected to exceed $100 billion in the next decade, the company could rebound if UBT251 and other candidates perform well.
See More
Novo Nordisk's New Drug Faces Competitive Pressure
- Clinical Trial Setbacks: Novo Nordisk's obesity drug CagriSema underperformed against Eli Lilly's Zepbound, achieving only a 23% average weight loss over 84 weeks compared to Zepbound's 25.5%, indicating challenges in maintaining competitiveness in the fast-growing weight loss market.
- Potential of UBT251: In a study conducted in China, UBT251 demonstrated a mean weight loss of up to 19.7% in just 24 weeks, leveraging a mechanism that mimics three gut hormones to enhance weight loss efficacy, suggesting it could outperform existing competitors if late-stage trials are favorable.
- Market Outlook Analysis: Despite promising initial results for UBT251, uncertainties remain regarding its approval in the U.S., and Eli Lilly's retatrutide has set a high bar with a 28.7% weight loss in 68 weeks, intensifying competitive pressures on Novo Nordisk.
- Industry Competitive Landscape: With the weight loss market projected to exceed $100 billion in sales over the next decade, Novo Nordisk must accelerate its drug development efforts to maintain its position as the second-leading player, even as its stock hovers near multi-year lows, indicating potential for recovery.
See More
Novo Nordisk and Hims End Feud, Announce Partnership
- Partnership Restoration: Novo Nordisk has decided to sell its weight-loss drug on Hims' telehealth platform, ending their public feud, with an official announcement expected on Monday, indicating a strategic shift in both companies' market approaches.
- Legal Dispute Context: Last month, Novo Nordisk sued Hims for marketing a compounded version of its new weight-loss pill, alleging patent violations related to the ingredient in Wegovy, highlighting the pharmaceutical industry's strong emphasis on intellectual property rights.
- Intensifying Market Competition: The weight-loss drug market is facing increased competition due to recent supply shortages, with the FDA planning to enhance scrutiny of copycat weight-loss drugs, potentially reshaping market dynamics and prompting companies to reassess their product strategies.
- Significant Stock Price Fluctuations: Hims' stock surged 39.77% to $22 in after-hours trading, while Novo Nordisk's stock rose 2.12% to $39.40, reflecting the market's positive response to the new partnership and investor interest in the weight-loss drug market outlook.
See More
